Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3143-3152

  Paick, Jae Seung ^a   Kim, Je Jong ^b   Kim, Sae Chul ^c   Moon, Ki Hak ^d   Min, Kweon Sik ^e   Park, Kwangsung ^f   Suh, Jun Kyu ^g   Yang, Dae Yul ^h  

^a Seoul National University Hospital   (South Korea)

^b Korea University Ansan Hospital   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Yeungnam University Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Inha University Hospital   (South Korea)

^h Hallym University   (South Korea)

Author keywords

Antihypertensives; Erectile dysfunction; Mirodenafil; PDE5 inhibitor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MIRODENAFIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LABORATORY TEST; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN;

EID: 77956289068     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01926.x     Document Type: Article

References (33)

1. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004, 171:2341-5.
2. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002, 5:19-24.
3. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270:83-90. NIH Consensus Conference
4. Araujo AB, Travison TG, Ganz P, Chiu GR, Kupelian V, Rosen RC, Hall SA, McKinlay JB. Erectile dysfunction and mortality. J Sex Med 2009, 6:2445-54.
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994, 151:54-61.
6. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek OR, Shabsigh R. Hypertension is associated with severe erectile dysfunction. J Urol 2000, 164:1188-91.
7. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: Prevalence and clinical correlates. Int J Impot Res 2000, 12:41-5.
8. Andersson K-E WG. Physiology of penile erection. Physiol Rev 1995, 75:191-236.
9. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol 1997, 20:26-33.
10. Cannon ROI. Role of nitric oxide in cardiovascular disease: Focus on the endothelium. Clin Chem 1998, 44:1809-19.
11. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000, 18:1865-9.
12. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001, 14:70-3.
13. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003, 92:47M-57M.
14. Porst H, Padma-Nathan H, Thibonnier M, Eardley I. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Eur Urol 2002, 152:599.
15. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-64.
16. Shin HI, Lee J, Kim DK. Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-npropoxyphenyl}-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin-4-one·2HCl (14CSK3530. 2 HCl). J Labelled Comp Radiopharm 2006, 49:1141-9.
17. Lee J, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism and excretion of 5 ethyl-2-{5-[4-(2-hydroxyethyl) piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK 3530) in rats. Rapid Commun Mass Spectrom 2007, 21:1139-49.
18. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008, 5:2672-80.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-30.
20. Fugl-Meyer AR, Lodnert G, Bränholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997, 9:141-8.
21. Park HJ, Park NC, Shim HB, Park JK, Lee SW, Park K, Kim SW, Moon KH, Lee DH, Yoon SJ. An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008, 5:2405-13.
22. Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005, 17:450-4.
23. Paick JS, Kim SW, Park YK, Hyun JS, Park NC, Lee SW, Park K, Moon KH, Chung WS. The efficacy and safety of Udenafil [zydena] for the treatment of erectile dysfunction in hypersensitive men taking concomitant antihypertensive agents. J Sex Med 2009, 6:3166-76.
24. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83:21C-8C.
25. Rohde G, Jordaan P. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. [Abstract]. Pharmacotherapy 2002, 22:418.
26. Vardi Y, Klein L, Nassar S, Sprecher E, Gruenwald I. Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology 2002, 59:747-52.
27. Patterson D, McInnes GT, Webster J, Mitchell MM, Macdonald TM. Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. Br J Clin Pharmacol 2006, 62:280-7.
28. Acevedo CG, Carrasco G, Burotto M, Rojas S, Bravo I. Ethanol inhibits L-arginine uptake and enhances NO formation in human placenta. Life Sci 2001, 68:2893-903.
29. Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: A single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther 2009, 31:1234-43.
30. Mikhailidis DP, Khan MA, Milionis HJ, Morgan RJ. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000, 16(1):s31-6. suppl
31. Srilatha B, Adaikan PG, Arulkumaran S, Ng SC. Sexual dysfunction related to antihypertensive agents: Results from the animal model. Int J Impot Res 1999, 11:107-13.
32. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003, 2:29-34.
33. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study. Am J Hypertens 2001, 14:27-31.